# Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

> **NCT00515411** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 111 (actual)

## Conditions studied

- Gastroesophageal Junction Adenocarcinoma
- Gastric Cancer

## Interventions

- **DRUG:** Docetaxel, Leucovorin, Fluorouracil, Cisplatin
- **DRUG:** Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen
- **DRUG:** Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab

## Key facts

- **NCT ID:** NCT00515411
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10-23
- **Primary completion:** 2018-10-26
- **Final completion:** 2018-10-26
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2019-12-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00515411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00515411, "Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00515411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*